Nieuws

Fierce Biotech49 m

Cancer biotech Prelude calls it curtains on lead SMARCA2 degrader

Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...